Physician profile
Jeet Lund
NPI 1275977753
$3,108.23
in general payments reported to CMS, 2019-2025
18 companies · $369 in 2025
The $369 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $579 · 2020: $28.33 · 2021: $236 · 2022: $1,858 · 2024: $38.00 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $406.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $838.09 | 2021-2022 | |
| Pulmonx Corporation | $805.00 | 2022-2025 | Zephyr Endobronchial Valve |
| Pinnacle Biologics, INC | $578.64 | 2022 | |
| Noah Medical Corporation | $139.55 | 2025 | Galaxy |
| Olympus America INC. | $139.44 | 2025 | |
| Mallinckrodt Enterprises LLC | $94.38 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $91.99 | 2019 | |
| United Therapeutics Corporation | $90.12 | 2019 | |
| Pfizer INC. | $87.39 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.68 | 2019 | |
| Gilead Sciences, INC. | $34.12 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.20 | 2019 | |
| Novartis Pharmaceuticals Corporation | $29.23 | 2019-2020 | |
| Glaxosmithkline, LLC. | $28.61 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $25.56 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $19.85 | 2019 | |
| Portola Pharmaceuticals, LLC | $17.52 | 2019 | |
| Mylan Specialty L.P. | $15.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeet Lund listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.